ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Cuproptosis illustrates tumor micro-environment features and predicts prostate cancer therapeutic sensitivity and prognosis

Cheng, Bisheng; Tang, Chen; Xie, Junjia; Zhou, Qianghua; Luo, Tianlong; Wang, Qiong*; Huang, Hai*广州医学院; 南方医科大学; 中山大学; 6
Life Sciences2023-7-15DOI: 10.1016/j.lfs.2023.121659
9被引8阅读
引用收藏
分享

摘要

Background: Prostate cancer (PCA) is a common malignant genitourinary tumor that significantly impacts patient survival. Cuproptosis, a copper-dependent programmed cell death mechanism, plays a vital role in tumor development, therapy resistance, and immune microenvironment regulation in PCA. However, research on cuproptosis in prostate cancer is still in its early stages.Methods: Using the publicly available datasets TCGA and GEO, we first acquired the transcriptome and clinical information of PCA patients. The expression of cuprotosis-related genes (CRG) was identified and a prediction model was established based on LASSO-COX method. The predictive performance of this model was evaluated based on Kaplan-Meier method. Using GEO datasets, we further confirmed the critical genes level in the model. Tumor responses to immune checkpoint (ICP) inhibitors were predicted based on Tumor Immune Dysfunction and Exclusion (TIDE) score. The Genomics of Drug Sensitivity in Cancer (GDSC) was utilized to forecast drug sensitivity in cancer cells, whereas the GSVA was employed to analyze enriched pathways related to the cuproptosis signature. Subsequently, the function of PDHA1 gene in PCA was verified.Results: A predictive risk model on basis of five cuproptosis-related genes (ATP7B, DBT, LIPT1, GCSH, PDHA1) were established. The progression free survival of low-risk group was obviously longer than the high-risk group, and exhibit better response to ICB therapy.Furthermore,PDHA1 is very important in the pathological process of PCA according to regressions analysis result, and the validation of external data sets were conducted. High PDHA1 expression patients with PCA not only had a shorter PFS and were less likely to benefit from ICB treatment, but they were also less responsive to multiple targeted therapeutic drugs. In preliminary research, PDHA1 knockdown significantly decreased the proliferation and invasion of PCA cells.Conclusion: This study established a novel cuproptosis-related gene-based prostate cancer prediction model that accurately predicts the prognosis of PCA patients. The model benefits individualized therapy and can assist clinicians in making clinical decisions for PCA patients. Furthermore, our data show that PDHA1 promotes PCA cell proliferation and invasion while modulating the susceptibility to immunotherapy and other targeted therapies. PDHA1 can be regarded as an important target for PCA therapy.

学科与关键词

关键词
CuproptosisPDHA1Prostate cancerImmunotherapyPrognosis
相关
加载中…
  • Comprehensive analysis of cuproptosis-related genes on bladder cancer prognosis, tumor microenvironment invasion, and drug sensitivity
    Wang, Honglei; Li, Jinqiao; Zi, Xiaolin; Yuan, Xueli*Frontiers in Oncology, 2023, 13: 1116305.被引 2
  • Comprehensive exploration of the involvement of cuproptosis in tumorigenesis and progression of neuroblastoma
    Zhou, Rui; Huang, Dongmei; Fu, Wen*; Shu, Fangpeng*BMC GENOMICS, 2023, 24(1): 715.
  • The LncRNA signature associated with cuproptosis as a novel biomarker of prognosis in immunotherapy and drug screening for clear cell renal cell carcinoma
    Zhang, Lishuo; Di, Longjiang; Liu, Jinhui; Lei, Xianli; Gu, Maoli; Zhang, Wenjing*; Wang, Yufu*Frontiers in Genetics, 2023, 14: 1039813.
查看全部 →

发表信息

论文状态
公开发表
期刊
Life Sciences
发表日期
2023-07-15
卷期
第 325 卷
页码
121659
DOI
10.1016/j.lfs.2023.121659
语言
ENGLISH
成果收录
SCIE
资助标注
National Natural Science Foundation of China [81974395, 82173036]; Guangdong Basic and Applied Basic Research Foundation [2019A1515011437]; International Science and Technology Cooperation Project Plan of Guangdong Province [2021A0505030085]; Sun Yat-Sen University Clinical Research 5010 Program [2019005]; Sun Yat-Sen Clinical Research Cultivating Program [201702]; Guangdong Province Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation [2020B1212060018OF006]; Guangdong Provincial Clinical Research Center for Urological Diseases [2020B1111170006]; Beijing Bethune Charitable Foundation [mnzl202001]; Guangzhou Science and Technology Key Ramp;D Project [202206010117]; Beijing CSCO Clinical Oncology Research Foundation [Y-tongshu2021/ms-0162]; Guangdong Province Natural Science Foundation [2023A1515011905]; National Science Fund for Distinguished Young Scholars [82203088]; China Postdoctoral Science Foundation [2022M713626, 2021TQ0388]

作者

  • C

    Cheng, Bisheng (第一作者)

    sun yat sen univ

  • T

    Tang, Chen

    sun yat sen univ

查看全部 7 位作者收起作者
  • X

    Xie, Junjia

    sun yat sen univ

  • Z

    Zhou, Qianghua

    sun yat sen univ

  • L

    Luo, Tianlong

    sun yat sen univ

  • W

    Wang, Qiong (通讯)

    southern med univ

  • H

    Huang, Hai (通讯)

    sun yat sen univ · 6 · guangzhou med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417